Madelon J H Metman
Overview
Explore the profile of Madelon J H Metman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ten Hoor M, Lin J, Metman M, Rodriguez Schaap P, Links T, Altena R, et al.
World J Surg
. 2024 Dec;
PMID: 39721719
Introduction: The 2015 American Thyroid Association guidelines recommend de-escalating surgical treatment for papillary thyroid cancer (PTC). We hypothesize that the Dutch PTC population might differ due to a restrictive diagnostic...
2.
Jager E, Metman M, Timmenga I, Zandee W, Jansen L, van Hemel B, et al.
Thyroid
. 2024 Dec;
35(1):87-96.
PMID: 39705074
Medullary thyroid cancer (MTC) is a rare cancer with variable disease course. To enable optimal care, centralization and consensus guidelines are essential. This study describes trends in the incidence, organization...
3.
Metman M, Jonker P, Sondorp L, van Hemel B, Sywak M, Gill A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Nov;
51(8):2384-2394.
PMID: 38017325
Purpose: Multifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the...
4.
Rodriguez Schaap P, Lin J, Metman M, Dreijerink K, Links T, Bonjer H, et al.
J Natl Cancer Inst
. 2023 Jun;
115(9):1071-1076.
PMID: 37267155
Background: The impact of multifocality and bilaterality on recurrence in patients with low-risk papillary thyroid cancer (PTC) is relevant when considering patients for a de-escalated treatment strategy: hemithyroidectomy instead of...
5.
Noltes M, Bader M, Metman M, Vonk J, Steinkamp P, Kukacka J, et al.
Eur J Nucl Med Mol Imaging
. 2023 Apr;
50(9):2736-2750.
PMID: 37039901
Purpose: Patient-tailored management of thyroid nodules requires improved risk of malignancy stratification by accurate preoperative nodule assessment, aiming to personalize decisions concerning diagnostics and treatment. Here, we perform an exploratory...
6.
Jonker P, Metman M, Sondorp L, Sywak M, Gill A, Jansen L, et al.
Eur J Nucl Med Mol Imaging
. 2022 Apr;
49(10):3557-3570.
PMID: 35389070
Purpose: Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be...
7.
Metman M, Vietor C, Seinen A, Berends A, Hemmer P, Kerstens M, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008320
The adrenal glands are common dissemination sites for metastasis of various solid tumors. Surgical treatment is often recommended because targeted therapies and immunotherapy are frequently ineffective for adrenal metastasis. We...
8.
Noltes M, Metman M, Jansen L, Peeperkorn E, Engelsman A, Kruijff S
VideoEndocrinology
. 2021 Jun;
8(2).
PMID: 34179223
Postoperative hypoparathyroidism is one of the most common complications after total thyroidectomy. In recent years, several techniques have been employed, trying to save parathyroid glands during thyroid surgery, such as...
9.
Noltes M, Metman M, Heeman W, Rotstein L, van Ginhoven T, Vriens M, et al.
Ann Surg
. 2021 Jun;
274(6):e659-e663.
PMID: 34145192
Objective: This study aims to generate a reproducible and generalizable Workflow model of ICG-angiography integrating Standardization and Quantification (WISQ) that can be applied uniformly within the surgical innovation realm independent...
10.
Loncar I, van Dijk S, Metman M, Lin J, Kruijff S, Peeters R, et al.
Thyroid
. 2021 Jan;
31(8):1219-1225.
PMID: 33430696
The worldwide incidence of papillary thyroid carcinoma (PTC) has increased. Efforts to reduce overtreatment follow two approaches: limiting diagnostic workup of low-risk thyroid nodules and pursuing active surveillance (AS) after...